Infinity Pharmaceuticals Inc. (NASDAQ: INFI), a clinical-stage biotechnology company, presents the updated data from its trial. The data comprises of Phase 2 MARIO-275 Trial in Urothelial Cancer (UC) and Phase 2 MARIO-3 Trial in Triple-Negative Breast Cancer (TNBC).
Update on MARIO-275
The company’s, Phase 2 study (placebo-controlled) monitored the efficacy and safety of eganelisib with nivolumab (Opdivo®) in platinum-refractory, in patients with high Urothelial Cancer (UC). The benefit of the trial was noted almost after a year. In addition, the company compared the results with the historical trial, which includes CHeckMate-275. The results were further supported by the free survival data, which the company represented to ASCO in February 2021.
Update on MARIO-3
The data from MARIO-3 indicates the company’s existing Phase 2 study monitoring eganelisib with atezolizumab (Tecentriq®) and nab-paclitaxel (Abraxane®) in patients with unresectable locally advanced or metastatic Triple Negative Breast Cancer (TNBC). As per the data, the clinical study trial reveals the strong data that it controls the disease, regardless of PD-L1 status. In addition, the results of MARIO-3 are in line with the results of MARIO-275.
Data indicates the efficacy of the trials.
Both the data indicate the improvement or impact on the patients who enrolled for the study in two different types of cancer. The data indicates that eganelisib increased the overall survival change of patients with metastatic urothelial cancer and prolonged progression in patients with TNBC. As per the data, it is evidence of eganelisib’s potential to improve the patients’ health with these two types of cancer. The resulting potential of both the drugs makes the company feel more confident about the future of eganelisib and its ability to achieve its vision of bringing better treatment for the patients. The data indicates the trials of MARIO-275 and MARIO-3 show a similar translation of control of the disease. In addition, it increases the life span of the patients suffering from the distinct type of cancer.
The company is on track to complete the enrolment of both these trials by the end of 2021. In addition, with most of the patients still undergoing treatment, Infinity Pharmaceuticals is expected to provide additional data in the time to come.
